Reviva Pharmaceuticals Holdings, Inc. to Present at Upcoming Virtual Investor Conferences
18 mars 2022 08h00 HE
|
Reviva Pharmaceuticals
- 5th Annual Neuroscience Innovation Forum - - BIO-Europe Spring® 2022 - CUPERTINO, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the...
Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2021 Financial Results and Recent Business Highlights
15 mars 2022 17h16 HE
|
Reviva Pharmaceuticals
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023 - $29.7 Million in Cash as of December 31, 2021 - CUPERTINO, Calif.,...
Reviva Pharmaceuticals Announces First Patients Dosed in Pivotal Phase 3 Study and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia
01 févr. 2022 06h00 HE
|
Reviva Pharmaceuticals
- RECOVER is a Phase 3, randomized, double-blind study with registrational intent - - Reviva anticipates expanding the clinical development of brilaroxazine into other neuropsychiatric indications - ...
Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Term Safety Trial Evaluating Brilaroxazine For The Treatment of Schizophrenia
10 janv. 2022 06h00 HE
|
Reviva Pharmaceuticals
- Brilaroxazine is a novel serotonin and dopamine receptor modulator currently being developed for diseases with dysfunctional serotonin signaling including neuropsychiatric and pulmonary indications...
Reviva Pharmaceuticals to Participate in the Upcoming January Virtual Investor Conferences
20 déc. 2021 07h00 HE
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Highlights
15 nov. 2021 08h15 HE
|
Reviva Pharmaceuticals
- Initiation of a pivotal Phase 3 trial evaluating the efficacy and safety of brilaroxazine for the treatment of schizophrenia expected by year-end - - Additional Phase 3 trial evaluating the...
Reviva Pharmaceuticals to Present at the Upcoming Benzinga Healthcare Small Cap Conference
15 sept. 2021 08h30 HE
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
02 sept. 2021 08h30 HE
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2021 Financial Results and Recent Business Highlights
16 août 2021 08h15 HE
|
Reviva Pharmaceuticals
-Closed Underwritten Public Offering of Common Stock and Warrants Resulting in Gross Proceeds of $34.5 Million -Expected to Initiate Pivotal Phase 3 Clinical Trial in Schizophrenia in Q4’21 -$35.8...
Reviva Added to Russell Microcap® Index
28 juin 2021 07h00 HE
|
Reviva Pharmaceuticals
CUPERTINO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva” or the “Company”), a clinical-stage pharmaceutical...